Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 31, Number 4—April 2025
Research
Antiviral Susceptibility of Influenza A(H5N1) Clade 2.3.2.1c and 2.3.4.4b Viruses from Humans, 2023–2024
Table 4
Susceptibility of HPAI A(H5N1) viruses isolated from humans to polymerase inhibitors in cell culture-based assay IRINA, 2023–2024 *
Influenza A(H5N1) virus | Mean EC50, nM |
|||
---|---|---|---|---|
PA-CEN inhibitor |
PB2 inhibitor |
|||
Baloxavir (fold change) | Tivoxavir (fold change) | Pimodivir (fold change) | ||
Clade 2.3.2.1c, median EC50, n = 7 | 0.55 | 0.52 | 0.40 | |
A/Cambodia/NPH230032/2023 | 0.56 ± 0.20 | 0.84 ± 0.23 | 0.06 ± 0.01 | |
A/Cambodia/2302009/2023 | 0.74 ± 0.25 | 0.43 ± 0.18 | 0.07 ± 0.02 | |
A/Cambodia/NPH230776/2023 | 0.54 ± 0.08 | 0.56 ± 0.22 | 0.37 ± 0.10 | |
A/Cambodia/KSH230332/2023 | 0.55 ± 0.12 | 0.52 ± 0.13 | 0.34 ± 0.14 | |
A/Cambodia/2311257/2023 | 0.62 ± 0.12 | 0.54 ± 0.17 | 0.40 ± 0.09 | |
A/Cambodia/24020155/2024 | 0.54 ± 0.16 | 0.52 ± 0.14 | 0.91 ± 0.31 | |
A/Cambodia/24020179/2024 |
0.40 ± 0.14 |
0.47 ± 0.12 |
0.45 ± 0.06 |
|
Clade 2.3.4.4b, median EC50, n = 7 | 0.83 | 0.88 | 1.32 | |
A/Chile/25945/2023 | 0.96 ± 0.28 | 1.07 ± 0.17 | 0.73 ± 0.18 | |
A/Texas/37/2024 | 1.06 ± 0.22 | 1.09 ± 0.09 | 1.66 ± 0.17 | |
A/Michigan/90/2024 | 0.57 ± 0.21 | 0.56 ± 0.22 | 1.48 ± 0.65 | |
A/Colorado/109/2024 | 0.44 ± 0.35 | 0.72 ± 0.30 | 1.32 ± 0.46 | |
A/Colorado/137/2024 | 0.95 ± 0.30 | 0.98 ± 0.24 | 1.51 ± 0.27 | |
A/Colorado/139/2024 | 0.70 ± 0.07 | 0.77 ± 0.19 | 1.19 ± 0.12 | |
A/California/134/2024 |
0.73 ± 0.12 |
0.47 ± 0.07 |
1.03 ± 0.30 |
|
Control viruses† | ||||
A/bald eagle/FL/2022 (H5N1)‡ | 0.42 ± 0.20 | 0.76 ± 0.29 | 0.46 ± 0.19 | |
A/Illinois/08/2018 (H1N1)pdm09 | 1.16 ± 0.24 | 1.46 ± 0.32 | 0.93 ± 0.22 | |
A/Illinois/08/2018 (H1N1)pdm09, PA-I38T | 137.05 ± 17.43 (116) | 72.86 ± 11.00 (50) | 0.49 ± 0.14 | |
A/New Jersey/24/2017 (H3N2) | 0.72 ± 0.14 | 0.57 ± 0.26 | 0.60 ± 0.25 | |
A/Pennsylvania/242/2017 (H3N2), PB2-S342R | 0.35 ± 0.10 | 0.29 ± 0.11 | 99.50 ± 27.26 (166) |
*Data shown are means (+SDs) of >3 experiments. Fold change was calculated from sequence-matched control virus. EC, effective concentration; HPAI, highly pathogenic avian influenza; IRINA, influenza replication inhibition neuraminidase-based assay; PA-CEN, PA cap-dependent endonuclease. †Control seasonal viruses were from Centers for Disease Control and Prevention Baloxavir Susceptibility Reference Virus Panel (no. FR-1678 ver1.1) and virus inventory. ‡Clade 2.3.4.4b A(H5N1) virus, A/bald eagle/Florida/W22–134-OP/2022 (GISAID ID no. EPI_ISL_15063846), was used as a control.
1These first authors contributed equally to this article.